Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2700 of 3173 entries
View as:

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age

Phase: N/A Priority: Normal
NCT ID: NCT00174252 Org: User:
Start: 02/28/05 End: 04/30/09 Due: 04/30/10

Sedation Of Adult Patients Undergoing Gastrointestinal Endoscopy: A Network Meta-analysis

Phase: N/A Priority: Normal
NCT ID: NCT03632330 Org: User:
Start: 02/05/18 End: 03/07/18 Due: 03/07/19

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05064800 Org: User:
Start: 09/21/21 End: 12/06/21 Due: 12/06/22

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Phase: N/A Priority: Normal
NCT ID: NCT05650476 Org: User:
Start: - End: - Due: -

A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06122194 Org: User:
Start: 11/23/23 End: 01/12/24 Due: 01/12/25

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00678210 Org: User:
Start: 07/31/08 End: 08/31/09 Due: 08/31/10

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

Phase: N/A Priority: Normal
NCT ID: NCT04909853 Org: User:
Start: 06/15/21 End: 10/07/21 Due: 10/07/22

A Study of PF-06873600 in People With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03519178 Org: User:
Start: 03/07/18 End: 10/30/24 Due: 10/30/25

Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin

Phase: N/A Priority: Normal
NCT ID: NCT00970593 Org: User:
Start: 09/02/09 End: 07/25/11 Due: 07/25/12

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

Phase: N/A Priority: Normal
NCT ID: NCT00576589 Org: User:
Start: 01/31/08 End: 09/30/08 Due: 09/30/09

Methods Study to Characterize Early Indicators of Weight Loss in People

Phase: N/A Priority: Normal
NCT ID: NCT00383253 Org: User:
Start: 10/31/06 End: 03/31/08 Due: 03/31/09

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Phase: N/A Priority: Normal
NCT ID: NCT05767905 Org: User:
Start: 03/17/23 End: 06/20/23 Due: 06/20/24

Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions

Phase: N/A Priority: Normal
NCT ID: NCT03073109 Org: User:
Start: 03/15/17 End: 09/16/19 Due: 09/16/20

Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT01783015 Org: User:
Start: 09/30/13 End: 08/31/14 Due: 08/31/15

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06974734 Org: User:
Start: 05/06/25 End: 07/27/29 Due: 07/27/30

Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule

Phase: N/A Priority: Normal
NCT ID: NCT01058824 Org: User:
Start: 04/30/09 End: 04/30/09 Due: 04/30/10

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

Phase: N/A Priority: Normal
NCT ID: NCT00220389 Org: User:
Start: 06/30/03 End: 06/30/07 Due: 06/30/08

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Phase: N/A Priority: Normal
NCT ID: NCT06989437 Org: User:
Start: 08/29/25 End: 01/07/30 Due: 01/07/31

A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06735742 Org: User:
Start: 04/12/25 End: 07/25/31 Due: 07/25/32

A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06733337 Org: User:
Start: 07/31/25 End: 06/22/29 Due: 06/22/30

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Phase: N/A Priority: Normal
NCT ID: NCT06807281 Org: User:
Start: 11/03/25 End: 02/22/32 Due: 02/22/33

An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria

Phase: N/A Priority: Normal
NCT ID: NCT01557283 Org: User:
Start: 09/30/11 End: 06/30/13 Due: 06/30/14

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05067972 Org: User:
Start: 10/07/21 End: 10/17/23 Due: 10/17/24

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02573259 Org: User:
Start: 02/10/16 End: 11/19/20 Due: 11/19/21

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

Phase: N/A Priority: Normal
NCT ID: NCT02997176 Org: User:
Start: 09/30/16 End: 02/12/20 Due: 02/12/21